CDK6 and breast carcinoma: In contrast, the drugs already approved for breast cancer abemaciclib, ribociclib, trilaciclib, and palbociclib bind directly to the protein encoded by the CDK6 gene, cyclin-dependent kinase 6 (CDK6).